Bliss Gvs Pharma Ltd. Share Price & Stock Analysis

Bliss Gvs Pharma Ltd. (BSE: 506197) is a Mumbai, Maharashtra-based company in the Non-Prescription Drugs industry. With a market capitalisation of ₹6,817 Cr, it ranks #725 by market cap among the 6,197 Indian listed companies on FinBizNet, and #3 of 9 in Non-Prescription Drugs. At ₹673.60 (as of 16 Nov 2026), the share price is 9.0% below its 52-week high of ₹739.90 and 426.7% above its 52-week low of ₹127.90. The share price is up 426.3% over one year and up 31.0% over three months.

Key Metrics

Current Price₹673.60
Market Cap₹6,817 Cr
BSE Code506197
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryPharmaceuticals > Non-Prescription Drugs
P/E Ratio53.9
Return on Equity11.60%
Return on Assets5.87%
52-Week Range₹127.90 – ₹739.90
1-Year Price Change+426.3%
3-Month Price Change+31.0%
Beta (1Y)0.94
Dividend Yield0.31%
HeadquartersMumbai, Maharashtra
Websitewww.blissgvs.com

Latest Quarterly Results — Q2 FY27

Revenue₹313 Cr
Net Profit₹53 Cr
Net Margin17.0%
EPS (Basic)₹4.92
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Bliss Gvs Pharma Ltd. Quarterly Revenue and Profit Trend

Bliss Gvs Pharma Ltd. reported revenue of ₹313 Cr in Q2 FY27, up 28.2% from ₹244 Cr in Q2 FY26 and up 9.7% from ₹286 Cr in Q1 FY27. It posted a net profit of ₹53 Cr for the quarter, against a net profit of ₹29 Cr in Q2 FY26 (up 86.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹198 Cr (Q4 FY25) to ₹313 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹313 Cr₹53 Cr17.0%
Q1 FY27₹286 Cr₹51 Cr18.0%
Q4 FY26₹257 Cr₹37 Cr14.4%
Q3 FY26₹218 Cr₹25 Cr11.4%
Q2 FY26₹244 Cr₹29 Cr11.7%
Q1 FY26₹207 Cr₹44 Cr21.4%
Q4 FY25₹198 Cr₹17 Cr8.4%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 50.07% of Bliss Gvs Pharma Ltd.'s shares as of Sept 2026, against 35.39% in Sept 2025 (+14.68 percentage points). Delivery averaged 100.0% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).

About Bliss Gvs Pharma Ltd.

Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, shampoo, soaps, sprays, and vaginal washes. In addition, it offers therapeutic products consisting of analgesics, antacids, anxiolytics, and haematinics; anti-bacterials, antibiotics, anti-diabetics, anti-diarrheals, anti-emetics, antifungals, anti-haemorrhoidals, anti-helmintics, anti-infectives, anti-inflammatories, anti-malarials

Products and Services

1. Pharmaceutical and Healthcare-This segment develops, manufactures, and markets pharmaceutical formulations. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. 2. Segment Adjustment-0 3. Health Care-This segment offers health care products. 4. Corporate-0

Business Segments

1. Pharmaceutical and Healthcare-100%

Bliss Gvs Pharma Ltd. vs Peers — Non-Prescription Drugs

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Glaxosmithkline Pharmaceuticals Ltd.₹44,982 Cr43.448.91%₹1,184 Cr+3.3%
Alembic Pharmaceuticals Limited (Aplltd)₹20,245 Cr30.512.36%₹2,603 Cr+11.7%
Bliss Gvs Pharma Ltd.₹6,817 Cr53.911.60%₹313 Cr+426.3%
Zota Health Care Ltd₹4,585 Crn/m-16.05%₹199 Cr-15.1%
Amrutanjan Health Care Ltd.₹1,467 Cr25.316.62%₹135 Cr-28.1%
Jenburkt Pharmaceuticals Ltd.₹433 Cr12.518.84%—-11.8%
Sat Kartar Life Limited₹256 Cr15.725.30%——
Vista Pharmaceuticals Ltd.₹40 Crn/m-10.82%—-37.1%
Welcure Drugs & Pharmaceuticals₹23 Crn/m-5.50%—-64.2%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Bliss Gvs Pharma Ltd.?

Bliss Gvs Pharma Ltd. is trading at ₹673.60, with a market capitalisation of ₹6,817 Cr.

Which sector does Bliss Gvs Pharma Ltd. belong to?

Bliss Gvs Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).

What are the key financial ratios of Bliss Gvs Pharma Ltd.?

Bliss Gvs Pharma Ltd. has a P/E of 53.9 and a return on equity of 11.60%.

What is the stock symbol of Bliss Gvs Pharma Ltd.?

Bliss Gvs Pharma Ltd. is listed on the BSE under the scrip code 506197.

How has Bliss Gvs Pharma Ltd.'s share price moved over the past year?

Bliss Gvs Pharma Ltd.'s share price is up 426.3% over one year and up 31.0% over three months. Its 52-week range is ₹127.90 to ₹739.90.

What were Bliss Gvs Pharma Ltd.'s latest quarterly results?

In Q2 FY27, Bliss Gvs Pharma Ltd. reported revenue of ₹313 Cr and net profit of ₹53 Cr, with basic EPS of ₹4.92 (consolidated, parsed from the company's exchange filing).

How have Bliss Gvs Pharma Ltd.'s revenue and profit changed over the past year?

Bliss Gvs Pharma Ltd. reported revenue of ₹313 Cr in Q2 FY27, up 28.2% from ₹244 Cr in Q2 FY26 and up 9.7% from ₹286 Cr in Q1 FY27.

What is the promoter holding in Bliss Gvs Pharma Ltd.?

Promoters held 50.07% of Bliss Gvs Pharma Ltd.'s shares as of Sept 2026, against 35.39% in Sept 2025 (+14.68 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.